Study of Efficacy, Safety and Tolerability of Crisaborole and PF-07038124 With and Without NBUVB in Vitiligo: A Phase 2A Randomized, Double-Blind, Vehicle-Controlled Clinical Trial
Latest Information Update: 14 Jun 2024
At a glance
- Drugs Crisaborole (Primary) ; PF 07038124 (Primary)
- Indications Vitiligo
- Focus Therapeutic Use
Most Recent Events
- 11 Jun 2024 Status changed from active, no longer recruiting to completed.
- 07 Feb 2024 Planned primary completion date changed from 1 Nov 2024 to 1 Jun 2024.
- 07 Feb 2024 Status changed from recruiting to active, no longer recruiting.